AAN 2026: Parkinson’s cell therapy trial shows sustained benefits
WHY IT MATTERS
If bemdaneprocel continues to show sustained benefits in larger trials, it could offer Parkinson's patients a one-time treatment option instead of daily medications, potentially improving quality of life and treatment adherence.
A company called BlueRock Therapeutics tested a new cell therapy called bemdaneprocel for Parkinson's disease. In a small early-stage trial, patients who received one dose of this therapy showed improvement in their movement symptoms, and these improvements lasted for up to three years. This is promising because it suggests a single treatment might help Parkinson's patients for a long time.
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel continues to show potential to control motor symptoms in people with Parkinson’s disease, with the benefits of a single dose sustained for up to three years in a small Phase 1 trial. These findings from the Phase 1 exPDite study (NCT04802733), presented by Harini Sarva, MD, a neurologist at […] The post AAN 2026: Parkinson’s cell therapy trial shows sustained benefits appeared first on Parkinson's News Today